APA (7th ed.) Citation

McGonigle, R., Naci, H., Siebert, M., Ouvina, M., Gutiérrez-Sacristán, A., Wagner, A. K., & Bourgeois, F. T. (2025). Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study. PLoS Medicine, 22(12), 1. https://doi.org/10.1371/journal.pmed.1004651

Chicago Style (17th ed.) Citation

McGonigle, Rylee, Huseyin Naci, Maximilian Siebert, Michelle Ouvina, Alba Gutiérrez-Sacristán, Anita K. Wagner, and Florence T. Bourgeois. "Pediatric Studies and Labeling Additions Required by the U.S. FDA for Novel Drugs Approved from 2011 to 2023: A Retrospective Cohort Study." PLoS Medicine 22, no. 12 (2025): 1. https://doi.org/10.1371/journal.pmed.1004651.

MLA (9th ed.) Citation

McGonigle, Rylee, et al. "Pediatric Studies and Labeling Additions Required by the U.S. FDA for Novel Drugs Approved from 2011 to 2023: A Retrospective Cohort Study." PLoS Medicine, vol. 22, no. 12, 2025, p. 1, https://doi.org/10.1371/journal.pmed.1004651.